Media coverage about AstraZeneca (NYSE:AZN) has been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than 6,000 blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of 2.00 on their scale. InfoTrie also gave news articles about the company an news buzz score of 7 out of 10, indicating that recent media coverage is likely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected AstraZeneca’s analysis:
- Moment Finally Arrived?: AstraZeneca PLC, (NYSE: AZN) (topstocksnews.com)
- Indicators in Focus on AstraZeneca PLC (LSE:AZN) as Price Index Touches 1.15237 (hartsburgnews.com)
- Global Axial Spondyloarthritis Drugs Market 2018 – AstraZeneca Plc, Eli Lilly and Company, Johnson & Johnson … (thefuturegadgets.com)
- Up or Down: – AstraZeneca PLC, (NYSE: AZN) (nysenewstoday.com)
- What Analysts Suggest About Astrazeneca Plc (AZN)? (appsforpcdaily.com)
A number of equities research analysts recently commented on the stock. Guggenheim assumed coverage on shares of AstraZeneca in a research report on Monday, October 8th. They set a “buy” rating for the company. ValuEngine raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Thursday, September 27th. Wolfe Research assumed coverage on shares of AstraZeneca in a research report on Tuesday, October 23rd. They set an “outperform” rating for the company. Zacks Investment Research cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price on shares of AstraZeneca in a research report on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the stock. AstraZeneca has an average rating of “Hold” and an average price target of $41.74.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.38. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The business had revenue of $5.34 billion for the quarter, compared to analyst estimates of $5.26 billion. During the same quarter in the prior year, the business posted $1.12 EPS. AstraZeneca’s revenue for the quarter was down 14.3% compared to the same quarter last year. Research analysts forecast that AstraZeneca will post 1.68 EPS for the current year.
In related news, major shareholder Plc Astrazeneca purchased 246,666 shares of the business’s stock in a transaction on Friday, September 28th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $3,699,990.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
ILLEGAL ACTIVITY WARNING: “AstraZeneca (AZN) Receives Daily Media Sentiment Score of 2.00” was published by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/26/astrazeneca-azn-receives-daily-media-sentiment-score-of-2-00.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Stock Selection – What is cash flow?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.